Astria Therapeutics (NASDAQ:ATXS) Price Target Raised to $28.00

Astria Therapeutics (NASDAQ:ATXS) had its target price increased by Oppenheimer from $26.00 to $28.00 in a research report sent to investors on Thursday morning,Benzinga reports. They currently have an outperform rating on the biotechnology company’s stock.

Several other research firms have also issued reports on ATXS. TD Cowen began coverage on shares of Astria Therapeutics in a research report on Monday, July 29th. They issued a “buy” rating and a $35.00 price target on the stock. Wedbush restated an “outperform” rating and set a $22.00 target price on shares of Astria Therapeutics in a research report on Tuesday, August 13th. Evercore ISI upgraded Astria Therapeutics to a “strong-buy” rating in a research report on Wednesday, August 14th. Finally, HC Wainwright reissued a “buy” rating and set a $16.00 price objective on shares of Astria Therapeutics in a report on Friday, September 27th. Five investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $25.60.

Astria Therapeutics Stock Performance

Shares of ATXS opened at $9.37 on Thursday. Astria Therapeutics has a fifty-two week low of $4.26 and a fifty-two week high of $16.90. The business has a 50-day moving average of $11.40 and a 200 day moving average of $10.62. The firm has a market cap of $528.66 million, a P/E ratio of -4.48 and a beta of 0.71.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in ATXS. Rhumbline Advisers raised its holdings in shares of Astria Therapeutics by 4.1% in the 2nd quarter. Rhumbline Advisers now owns 65,375 shares of the biotechnology company’s stock valued at $595,000 after acquiring an additional 2,556 shares in the last quarter. Ameritas Investment Partners Inc. grew its stake in shares of Astria Therapeutics by 135.6% during the first quarter. Ameritas Investment Partners Inc. now owns 4,971 shares of the biotechnology company’s stock valued at $70,000 after buying an additional 2,861 shares during the last quarter. Quest Partners LLC increased its holdings in shares of Astria Therapeutics by 3,310.6% in the second quarter. Quest Partners LLC now owns 3,206 shares of the biotechnology company’s stock worth $29,000 after buying an additional 3,112 shares during the period. American International Group Inc. lifted its stake in shares of Astria Therapeutics by 49.4% in the 1st quarter. American International Group Inc. now owns 24,565 shares of the biotechnology company’s stock valued at $346,000 after acquiring an additional 8,122 shares during the last quarter. Finally, Bank of New York Mellon Corp increased its stake in Astria Therapeutics by 6.9% in the 2nd quarter. Bank of New York Mellon Corp now owns 139,071 shares of the biotechnology company’s stock worth $1,266,000 after purchasing an additional 8,965 shares during the period. Institutional investors own 98.98% of the company’s stock.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.